Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Merck (MRK) to Acquire cCAM Biotherapeutics in ~$605M Deal
July 28, 2015 7:58 AM EDTMerck (NYSE: MRK) and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies.
Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95 million in cash. In addition, cCAM shareholders of record are eligible to receive a total of up to $510 million associated with the attainment of certain clinical development, regulatory and commercial... More
